APA (7th ed.) Citation

M, L., A, Q., SK, V., T, G., A, A., Y, W., . . . K, S. (2026). Neoadjuvant/adjuvant relugolix and enzalutamide for the treatment of high-risk locally advanced prostate cancer: Study protocol of the RENAPCA phase Ib trial. BMJ open, 16(4), e112623. https://doi.org/10.1136/bmjopen-2025-112623

Chicago Style (17th ed.) Citation

M, Loper, Qadar A, Vesely SK, Gunter T, Ayanambakkam A, Wen Y, Cookson M, and Stratton K. "Neoadjuvant/adjuvant Relugolix and Enzalutamide for the Treatment of High-risk Locally Advanced Prostate Cancer: Study Protocol of the RENAPCA Phase Ib Trial." BMJ Open 16, no. 4 (2026): e112623. https://doi.org/10.1136/bmjopen-2025-112623.

MLA (9th ed.) Citation

M, Loper, et al. "Neoadjuvant/adjuvant Relugolix and Enzalutamide for the Treatment of High-risk Locally Advanced Prostate Cancer: Study Protocol of the RENAPCA Phase Ib Trial." BMJ Open, vol. 16, no. 4, 2026, p. e112623, https://doi.org/10.1136/bmjopen-2025-112623.